HCPLive Network

Lawrence Brandt, MD, on Fecal Microbiota Transplant Study, Part I

Lawrence Brandt, MD, professor of medicine and surgery at the Albert Einstein College of Medicine in New York City, discusses a study on the outcomes of fecal microbiota transplants on almost 100 patients across the country with refractory Clostridium difficile colitis. He explains that 91 percent of the patients experienced prompt relief. Including those who underwent a second transplant or a post-transplant course of medication, 98.3 percent of the patients experienced relief. This video was shot at the annual scientific conference of the American College of Gastroenterology.



Related Videos
In this video, Lawrence Brandt, MD, professor of medicine and surgery at the Albert Einstein College of Medicine in New York City, discusses the safety of fecal transplant as well as its applications to conditions other than Clostridium difficile colitis.
In this video, Lawrence Brandt, MD, professor of medicine and surgery at the Albert Einstein College of Medicine in New York City, discusses the safety of fecal transplant as well as its applications to conditions other than Clostridium difficile colitis.
In this video, Mark Mellow, MD, medical director of the Integris Digestive Health Center in Oklahoma City, discusses a study in which he followed up with patients who underwent fecal microbiota transplants to treat recurrent Clostridium difficile infection.
$AD300x250BB$